stockrowOruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Return on assets
Oruka Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −17.8%, up 6.1 percentage points from fiscal 2025 (−23.8%). Over the past ten years it has ranged from −100.0% (fiscal 2017) to −13.2% (fiscal 2023); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −23.8% | 14.75 |
| FY2024 | −38.6% | (25.40) |
| FY2023 | −13.2% | 7.07 |
| FY2022 | −20.3% | 16.42 |
| FY2021 | −36.7% | (3.65) |
| FY2020 | −33.0% | 38.35 |
| FY2019 | −71.4% | 11.30 |
| FY2018 | −82.7% | 17.28 |
| FY2017 | −100.0% | (48.73) |
| FY2016 | −51.2% | (10.14) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| ORKA Oruka Therapeutics, Inc. | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. compare | −18.9% |
| AXSM Axsome Therapeutics, Inc. compare | −21.0% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)